Speaker Snapshots

Speaker Snapshots

Thursday September 13

 

Dr. Ted Warkentin is a Professor in the Department of Medicine at McMaster University and the Regional Director of Transfusion Medicine in the Hamilton Regional Laboratory Medicine Program.  He was the Winner of the 2015 Prix Galien Canada, awarded to Canadian scientists who have made significant advances in pharmaceutical research, for his work in heparin-induced thrombocytopenia.

 

 

 

Dr. Kevin Song is an Associate Professor of Medicine at  the University of British Columbia and a Member of the Leukemia/BMT Program of BC.  He is the Provincial Lead for multiple myeloma, amyloidosis and other plasma cell dyscrasias; his research focus is on new treatment strategies for these disorders.

 

 

 

Dr. Ruben Mesa has been a leading MPN specialist for more than 20 years and is chair of the NCCN panel that published US guidelines on diagnosis and treatment of myelofibrosis.  He has been principal or co-principal investigator in 70 clinical trials that have led to FDA approval of numerous cancer drugs.

 

 

 

Dr. Robert Gale developed the bone marrow transplant program at UCLA in the 1970s and was the Chair of the Scientific Advisory Committee of the IBMTR for 17 years.  He was involved in the medical response to the Chernobyl Nuclear accident in 1986 and became the President of the Armand Center for Advanced Studies in Nuclear Energy and Health from 1986-1993. He has worked extensively as a consultant to pharmaceutical companies over the past two decades and is visiting Professor at Imperial College of London in the UK.

Friday September 14

 

Dr. Roland Walter is a Member of the Clinical Research Division at Fred Hutchison Cancer Research Center with a focus on translational research in AML.  His central areas of interest are the study of molecular and phenotypic characteristics of AML progenitors, detection of minimal residual disease and novel immunotherapies in AML.

 

 

 

Dr. Rebecca Kruse-Jarres is the Director of the Washington Center for Bleeding Disorders and is on the Board of Directors of the Hemostasis and Thrombosis Research Society.  Her research interest is coagulation inhibitor development and treatment in congenital and acquired hemophilia.

 

 

 

Dr. Peter Lansdorp is recognized as one of the world’s experts in telomere biology.  His laboratory developed the technique for measuring telomere length by peripheral blood fluorescence in-situ hybridization. His research continues to focus on the role of telomeres and the telomerase complex in normal aging, tumour progression and genetic hematological diseases.

 

 

Dr. David Lillicrap is a  Professor at Queens University in Kingston, ON and a Canada Research Chair in Molecular Hemostasis.  His research interests are directed at better understanding the coagulation system through the use of molecular genetics and molecular biology.  He has added extensively to the literature on von Willebrand Factor biology and has a keen interest in gene therapy in hemophilia.

 

 

Dr. Christina Peters is a Professor of Pediatrics in the Department of Stem Cell Transplantation at St. Anna Children’s Hospital in Vienna, Austria.  She is the Chair of the EBMT Pediatric Diseases Working Group and Principal Investigator of active EBMT and IBFM studies directed at the treatment of pediatric leukemias and hemoglobinopathies.

 

 

Professor Adrian Newland developed the Leukaemia and BMT Unit in the early 1980s at Barts and London NHS Trust where he became the Head of Haematology in 1995.  Beyond hematologic malignancies, his research interests involve the study of the molecular basis of autoimmune thrombocytopenia and novel treatments for this condition.

 

 

Dr. Joseph Connors, after 37 years at the British Columbia Cancer Agency, is retiring in 2018.  He became the Head of the Lymphoma Tumour Group at the BCCA in 1986 and the Clinical Director of the Centre for Lymphoid Cancer in 2000. He has pioneered therapies for Hodgkin and non-Hodgkin lymphoma over the past three decades and has been recognized as one of the World’s Most Influential Scientific Minds by Clarivate Analytics.

 

Dr. Jeffrey Lipton is Professor of Medicine at University of Toronto and former Director of the Allogeneic Blood and Marrow Transplant Service at Princess Margaret Hospital.  He remains the Lead of the Chronic Myeloid Leukemia Group, and has had extensive involvement in phase I, II and III studies evaluating therapies in CML.

Dr. Julien Haroche is a Professor of Medicine at Pitié-Salpêtrière Hospital in Paris and a recognized world expert in Erdheim-Chesterman disease (ECD) as well as other histiocytoses.  He was instrumental in delineating the characteristic gene mutations found in these disorders and was a driving force for the studies evaluating BRAF inhibitors in ECD.

Saturday September 15

 

Dr. Phillip Scheinberg is the Head of the Division of Hematology at Hospital A Beneficência Portuguesa de São Paulo in Brazil.  He had extensive experience with ground-breaking studies evaluating immunosuppressive therapies in aplastic anemia during his decade at the NIH in Bethesda, Maryland.

 

 

 

Dr. Thomas Loughran is the Director of the University of Virginia Cancer Center.  He did his Hematology/Oncology Fellowship and then became a Faculty Member at the Fred Hutchison Cancer Research Center where, in 1985, he discovered Large Granular Lymphocyte (LGL) leukemia.  He has published extensively on diagnosis and management of the condition and is acknowledged as the world expert on LGL leukemia.

 

 

Dr. Ralph Green is the Director of UC Davis Diagnostics and a recognized expert in the diagnosis and treatment of nutritional deficiency anemia.  In this capacity, he has been a consultant to the World Health Organization and to the US National Institute of Health Working Groups on the Microbiome and Biomarkers of Nutritional Development.

 

 

Dr. Michael Grever is Co-Leader of the Experimental Therapeutics Program at Ohio State University Cancer Center.  His research has focused on drug development in CLL and Hairy cell leukemia, including the initial phase I and II studies of purine analogues, histone deacetylase inhibitors, cyclin-dependent kinase inhibitors and BRAF inhibitors.

 

 

Dr. Shannon Maude is a Pediatric Oncologist in the Cancer Center at the Children’s Hospital of Philadelphia (CHOP).  She is the Lead of the Shannon Maude Research Program that is focused on developing new immunotherapies and targeted cancer therapies – including CAR T-cell treatment – in acute lymphoblastic leukemia.

 

 

 

Dr. Joseph Mikhael moved from the Mayo Clinic in Scottsdale, Arizona in 2018 to become the Chief Medical Officer of the International Myeloma Foundation.  His research interests include medical education and pharmacoeconomics but he is best known for his work in multiple myeloma and related plasma cell disorders.  He has been Principal Investigator in a number of clinical trials in multiple myeloma that have influenced treatment paradigms for both newly diagnosed and relapsed/refractory myeloma.

 

 

Dr. Marco Mielcarek is the Medical Director of the Adult Blood and Marrow Transplant Program of the Seattle Cancer Care Alliance.  His research is focused on new strategies for the prevention and treatment of graft-versus-host disease.  His most recent studies have examined the value of pre-treatment of donors with Atorvastatin and the use of timed post-transplantation high-dose Cyclophosphamide.

 

 

Dr. Nicholas Kassebaum is a member of the Institute for Health Metrics and Evaluation at the University of Washington.  He is a lead investigator in the landmark Global Burden of Disease study that is examining the burden of anemia, hemoglobinopathies and other diseases as well as evaluating the effectiveness and cost of interventions.

 

 

Dr. Rafael Bejar is an Assistant Professor at UC San Diego with a laboratory that is focused on understanding genetic changes that cause hematologic malignancies and ultimately lead to their progression.  He is the Principal Investigator on an NIH study that is characterizing the genetic alterations in myelodysplastic syndrome.

 

 

Dr. Mikkael Sekares is the Director of the Leukemia Program and Vice Chair for Clinical Research at the Cleveland Clinic.  He was the Chair of the Oncologic Drugs Advisory Committee of the FDA and his research interests focus on the treatment of myelodysplastic syndrome and elderly AML.  He has been the national Principal Investigator on multiple phase I and II studies evaluating novel treatments in these disorders.

 

 

 

Dr. Dominick Amato is the Director of the Centre for Gaucher Disease at Mt. Sinai Hospital in Toronto.  He is a leading specialist in this rare disorder and has been an investigator in studies evaluating both intravenous enzyme replacement and oral substrate reduction therapy.

Sunday September 16

 

Dr. Christopher Patriquin is a Hematologist at University Health Network in Toronto, Ontario and co-Chair of the Canadian PNH Network.  He is the National Coordinator of the global PNH Registry and a member of the Canadian Apheresis Group’s Thrombotic Microangiopathy Working Group.

 

 

 

Dr. Lynda Foltz is the Head of the Division of Hematology at St. Paul’s Hospital in Vancouver, BC.  She has been the site’s Principal Investigator on multiple MPN clinical trials and is a founding Executive Member of the Canadian MPN Group.

 

 

 

Dr. Catherine Hayward is a Professor at McMaster University in Hamilton, Ontario.  Her research focuses on the molecular aspects of hemostasis and platelet function.  Her laboratory’s central theme is the study of stored proteins, in particular Multimerin 1, in order to understand their role in bleeding and thrombosis in health and disease.

 

 

 

Dr. Elias Jabbour is an Associate Professor at MD Anderson Cancer Center.  His research focuses on novel therapies in acute lymphoblastic leukemia (ALL).  He has been the Section Chief of ALL in the Department of Leukemia since 2015 and was an investigator in the pivotal trials evaluating Blinatumomab and Inotuzumab in relapsed/refractory ALL.